Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002936 · ClinicalTrials.gov registry record · Phase 1
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002936 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute.
The verdict
NCT00002936, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating patients with HIV-related cancer.
Interventions
- DRUG etoposide
- DRUG altretamine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002936
The ClinicalTrials.gov registry entry for NCT00002936 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.
NCT00002936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002936 about?
NCT00002936 is a clinical study titled "Altretamine and Etoposide in Treating Patients With HIV-Related Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating patients with HIV-related cance...
What is the current status of trial NCT00002936?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-07.
What interventions are being tested in trial NCT00002936?
The interventions under investigation include: etoposide (DRUG), altretamine (DRUG).
Who is sponsoring clinical trial NCT00002936?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.